- Home
- ROIV vs VLTO Comparison
ROIV vs VLTO Comparison
Compare ROIV & VLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | VLTO |
|---|---|---|
| Founded | 2014 | 2023 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 22.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | VLTO |
|---|---|---|
| Price | $26.32 | $92.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $27.44 | ★ $111.25 |
| AVG Volume (30 Days) | ★ 6.9M | 2.3M |
| Earning Date | 02-06-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 0.56% |
| EPS Growth | N/A | ★ 12.57 |
| EPS | N/A | ★ 3.76 |
| Revenue | $13,310,000.00 | ★ $5,503,000,000.00 |
| Revenue This Year | N/A | $8.16 |
| Revenue Next Year | $741.42 | $5.66 |
| P/E Ratio | ★ N/A | $24.61 |
| Revenue Growth | N/A | ★ 5.97 |
| 52 Week Low | $8.73 | $83.87 |
| 52 Week High | $27.94 | $110.11 |
Technical Indicators
Market Signals| Indicator | ROIV | VLTO |
|---|---|---|
| Relative Strength Index (RSI) | 66.81 | 39.51 |
| Support Level | $26.31 | $91.64 |
| Resistance Level | $27.94 | $95.56 |
| Average True Range (ATR) | 0.97 | 3.02 |
| MACD | 0.46 | -0.46 |
| Stochastic Oscillator | 79.45 | 32.21 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About VLTO Veralto Corp
Veralto is a diversified industrial firm organized into two segments: water quality, product quality, and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.5 billion in revenue in 2025.